hotspot -WSS

hotspot

author：focus 2025-09-28 17:06:52 - browse：34

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Mirador, a new biotech startup, launches with $400 million

leisure time

WSS

CRISPR technology availability, affordability needs to be expanded

How a scoliosis diagnosis changed the life of one young dancer

Ahead of JPM, here's who's profiting most in health care

Chinese researcher claims birth of first gene

CRISPR technology availability, affordability needs to be expanded

'Patient friction coefficient' can gauge a clinical trial's patient burden

focus

hotspot

explore

At least 13 dead in Texas as scorching temps continue

CRISPR technology availability, affordability needs to be expanded

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

U.K. officials, researchers try to ease path for bespoke genetic treatments

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pregnancy ages women, but effects reverse after delivery

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Psychedelics group wrestles with new pharma identity

GSK Flovent asthma inhalers replaced by authorized generics

Wikipedia

Texas board proposes rules on abortion law emergency exemption

New weight loss drugs work. But how can they best be used?

Asbestos ban is immediate, but health effects will linger for decades

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

AdventHealth escalates lawsuit against insurance vendor Multiplan

Yancopoulos of Regeneron works to expand Dupixent success

leisure time

leisure time

leisure time

entertainment